Omeros (OMER) EBITDA Margin (2010 - 2026)

Omeros (OMER) posted EBITDA Margin of 176.09% for Q1 2026, up 52.48% sequentially from 370.6% in Q2 2022.

Omeros (OMER) EBITDA Margin (2010 - 2026) Analysis & Trends

Omeros has reported EBITDA Margin for 14 years, with the latest figure at 176.09% in Q1 2026.

  • Quarterly EBITDA Margin changed N/A year-over-year to 176.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 389.94% (down 64935.0% YoY) and the FY2020 annual result came in at 212.59%, down 8197.0% from the prior year.
  • EBITDA Margin rose to 176.09% in Q1 2026 per OMER's latest filing, from 370.6% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 176.09% in Q1 2026 and troughed at 500.94% in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 37.40%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 30.15%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 31.68%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 19.06%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -77,569,866.34%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.75%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 17.93%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -0.36%
10 Omeros 1.24 Bn 1.24 Bn 27.73 Mn 0.26%

Historic Data

Download Data
DateValue
Jun 30, 2026 0.26%
Mar 31, 2026 -176.09%
Jun 30, 2022 -370.60%
Mar 31, 2022 -500.94%
Dec 31, 2021 53.69%
Sep 30, 2021 -132.74%
Jun 30, 2021 -158.24%
Mar 31, 2021 -215.04%
Dec 31, 2020 -318.06%
Sep 30, 2020 -97.37%
Jun 30, 2020 -204.58%
Mar 31, 2020 -100.59%
Dec 31, 2019 -70.93%
Sep 30, 2019 -37.18%
Jun 30, 2019 -34.90%
Mar 31, 2019 -88.34%
Dec 31, 2018 -83.91%
Sep 30, 2018 -769.14%
Jun 30, 2018 -1,849.97%
Mar 31, 2018 -1,743.64%